Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Drug Profile

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Alternative Names: C10; C9; C9A; CFAK-C10; CFAK-C4; CFAK-C9; CFAK-C9a; CFAK-Y15; Chloropyramine; Chloropyramine hydrochloride; FAK inhibitors - CureFAKtor; FAK technology platform - CureFAKtor; Y15

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureFAKtor Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Preclinical for Solid tumours and Pancreatic cancer in USA (PO)
  • 14 Nov 2011 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) ,,
  • 23 Jun 2011 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology (ECCO/ESMO-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top